Alcon Receives Positive NICE Recommendation for Jetrea

Alcon, the global leader in eye care, and second largest division of Novartis NVS, is pleased that the National Institute for Health and Care Excellence (NICE) has recommended Jetrea® (ocriplasmin) as a clinically and cost-effective treatment option for eligible patients suffering from vitreomacular traction including when associated with macular hole. With this final NICE guidance, Jetrea® is now recommended for use within the National Health Service (NHS) in England and Wales as the first and only pharmacological treatment for this sight-threatening eye condition. "We are very pleased by the NICE decision, as Jetrea® represents a breakthrough treatment option See full press release